收藏 分销(赏)

化学物危险性评价的进展.ppt

上传人:仙人****88 文档编号:14770439 上传时间:2026-11-18 格式:PPT 页数:43 大小:601.50KB 下载积分:10 金币
下载 相关
化学物危险性评价的进展.ppt_第1页
第1页 / 共43页
化学物危险性评价的进展.ppt_第2页
第2页 / 共43页


点击查看更多>>
资源描述
,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Latest Development in Dose Response Assessment in Chemical Risk Assessment,化学物危险性评价的最新进展,赵启宇,(Q.Jay Zhao),M.P.H,Ph.D.,DABT,U.S.Environmental Protection Agency,Office of Research and Development,National Center for Environmental Assessment,Disclaimer,声明,Statements and opinions expressed in this presentation are those of the author and do not necessarily reflect the official position of the organization with which the author is affiliated.,HAZARD,IDENTIFICATION,DOSE RESPONSE,ASSESSMENT,EXPOSURE,ASSESSMENT,RISK,CHARACTERIZ-,ATION,BEST AVAILABLE,TECHNOLOGY,ENGINEERING,OPTIONS,PUBLIC RESPONSE,POLITICAL,CONSIDERATIONS,NAS 1983,COST,危险性评价,/,管理,常用国际安全标准名称,美国食品药品管理局,(US,FDA):,可接受每日,摄入量,(acceptable daily intake,ADI),美国环境保护署,(US EPA):,参考剂量,(reference dose,RfD),或参考浓度,(reference concentration,RfC),美国毒物与疾病登记署,(ATSDR):,最,低,危险水平,(minimum,risk level,MRL),加拿大卫生部,(Health,Canada):,每日容许摄入量,/,浓度,(tolerable,daily intake/concentration,TDI/TDC),世界卫生组织,(WHO):,可接受每日摄入量,(acceptable,daily intake,ADI),国际化学品安全司,(IPCS/WHO):,容许摄入量,(tolerable,intake,TI),Traditional Noncancer Dose Response Assessment,非致癌物评价的传统方法,非致癌物反应,有阈值,The agency most often assumes that noncarcinogenic and/or,nonmutagenic,changes,have a threshold,.That is,there is a dose level below which a response is unlikely because homeostatic,compensation and adaptive mechanisms in the cell protect against toxic effects.,剂量反应关系,FAT IN LIVER CELLS,NOEL,NOAEL,%,R,E,S,P,O,N,S,E,暴露剂量或浓度,MINIMAL LYMPHOCYTE INFILTRATION,ENZYME CHANGE,(CRITICAL EFFECT),CONVULSIONS,FEL,LOAEL,RfD/RfC,UF x MF,NOAEL/LOAEL,RfD=,UF,8,NOAEL=No observed adverse effect level,(最大无有害作用剂量),LOAEL=Lowest observed adverse effect level,(最低有害作用剂量),UF =Uncertainty factor,(不确定系数),参考剂量,(,RfD,),的计算,不确定系数的分类,(U.S.EPA),UF,*外推,HAverage Human to Sensitive Human,人类个体差异,AAnimal to Human,实验动物与人之间差异,SSub-chronic to Long-term Exposure,亚慢性到慢性实验外推,LLOAEL to NOAEL,最低有害作用剂量到最大无有害作用剂量外推,DMinimum to Complete Database,数据库完整性,*,These factors are as used by the U.S.EPA.Other health organizations use similar factors.In EPA,the maximum UF for any given database is 3,000.Databases weaker than this are judged too uncertain to estimate RfD/RfCs.,Latest Development in Dose Response Assessment,非致癌物评价的最新进展,NOAEL/LOAEL,or BMD,RfD=,UF,11,NOAEL=No observed adverse effect level,LOAEL=Lowest observed adverse effect level,UF =Uncertainty factor,BMD =Benchmark Dose,(基准剂量),参考剂量,(,RfD,),的计算,12,NOAEL,0,0.2,0.4,0.6,0.8,1,0,50,100,150,200,Fraction Affected,dose,Gamma Multi-Hit Model with 0.95 Confidence Level,17:04 11/14 2005,Gamma Multi-Hit,每组样本量为,50,的实验,13,NOAEL,0,0.2,0.4,0.6,0.8,1,0,50,100,150,200,Fraction Affected,dose,Gamma Multi-Hit Model with 0.95 Confidence Level,Gamma Multi-Hit,每组样本量为,10,的实验,14,0,0.2,0.4,0.6,0.8,1,0,50,100,150,200,Fraction Affected,dose,Gamma Multi-Hit Model with 0.95 Confidence Level,17:04 11/14 2005,BMDL,BMD,Gamma Multi-Hit,NOAEL,BMR,每组样本量为,50,的实验,15,NOAEL,每组样本量为,10,的实验,0,0.2,0.4,0.6,0.8,1,0,50,100,150,200,Fraction Affected,dose,Gamma Multi-Hit Model with 0.95 Confidence Level,BMDL,BMD,Gamma Multi-Hit,16,Benchmark Dose,(基准剂量),Goal,目的,Define a point of departure(POD)that is relatively independent of study design.,BMD Definition,基准剂量的定义,An estimate of the dose or concentration that produces a predetermined change in response rate of an adverse effect(called the benchmark response or BMR)compared to background.,For example,an estimate of the dose that causes a 10%increase in the number of animals developing fatty liver compared with untreated animals.,BMDL Definition,基准剂量下限值的定义,95%Lower-Bound Confidence Limit on the BMD.,Point of Departure,起始点,Fit dose-response curve to the data(central estimate),BMD,10,=benchmark dose corresponding to 10%extra response,Lower confidence limit on dose corresponding to 10%response(BMDL,10,),Point of departure for extrapolation from observed animal data,NOAEL/LOAEL,or BMDL,10,RfD=,UF,18,NOAEL=No observed adverse effect level,LOAEL=Lowest observed adverse effect level,UF =Uncertainty factor,BMDL =benchmark dose lower confidence limit,(基准剂量下限),参考剂量,(,RfD,),的计算,NOAEL/LOAEL or BMDL,10,RfD=,UF,20,NOAEL=No observed adverse effect level,LOAEL=Lowest observed adverse effect level,UF =Uncertainty factor,(不确定系数),BMDL =benchmark dose lower confidence limit,参考剂量,(,RfD,),的计算,不确定系数的分类,(U.S.EPA),UF,*外推,HAverage Human to Sensitive Human,人类个体差异,AAnimal to Human,实验动物与人之间差异,SSub-chronic to Long-term Exposure,亚慢性到慢性实验外推,LLOAEL to NOAEL,最低有害作用剂量到最大无有害作用剂量外推,DMinimum to Complete Database,数据库完整性,*,These factors are as used by the U.S.EPA.Other health organizations use similar factors.In EPA,the maximum UF for any given database is 3,000.Databases weaker than this are judged too uncertain to estimate RfD/RfCs.,22,External,dose,Internal,dose,Target organ,responses,Toxic,Response,Target organ,metabolism,Target organ,dose,Toxicokinetics,毒物代谢动力学,Toxicodynamics,毒物动态学,External,dose,Toxic,Response,Uncertainty Factor,Data derived uncertainty factor,基,于数据的不确定系数,(early days),Chemical specific adjustment factor,化学物特异性调整系数,(latest term),Default Value Framework,100-fold uncertainty factor,Interspecies Differences,10-fold,Interindividual Variability,10-fold,Toxicokinetics,AK,10 E0.6,(4.0),Toxicodynamics,HD,10 E0.5,(3.16),Toxicokinetics,HK,10 E0.5,(3.16),Toxicodynamics,AD,10 E0.4,(2.5),AK,AF,=,AUC,A,or,Cmax,A,or,Cl,H,AUC,H,or,Cmax,H,or,Cl,A,实验动物与人之间差异,(,毒物代谢动力学,),AUC:area under the curve,时间,-,浓度峰下面积,Cmax,:,最高浓度,Cl,:clearance,清除率,26,AUC after administration of a single dose extrapolated to infinity,Estimate AUC from a Single Dose Extrapolation,Time(hr),Log Tissue Concentration(,ng,/L),Peak Concentration:,Cmax,AUC,A,rea,U,nder the,C,oncentration*Time,Curve,0.1,0.2,2 3,C,0,T,1/2,=1 hr,T,1/2,=0.693/K,el,V,d,=dose,i.v,./C,0,Cl,=,Vd,*,K,el,TK Jargon Demystified,Uncertainty Factors in the Development of Subthreshold Doses,UFs,Health Canada,IPCS,RIVM,ATSDR,EPA,Interindividual(H),10,(3.16 x 3.16),10,(3.16 x 3.16),10,10,10,(3.16 x 3.16),Interspecies(A),10,(2.5 x 4.0),10,(2.5 x 4.0),10,10,10,(3.16 x 3.16),Subchronic to chronic(S),1-100,1-100,10,NA,10,LOAEL to NOAEL(L),10,10,10,Incomplete Database(D),NA,NA,10,Modifying Factor(MF),1-10,1-10,NA,NA,0 to,10,(discontinued),Default Value Framework,100-fold uncertainty factor,Interspecies Differences,10-fold,Interindividual Variability,10-fold,Toxicokinetics,AK,10 E0.6,(4.0),Toxicodynamics,HD,10 E0.5,(3.16),Toxicokinetics,HK,10 E0.5,(3.16),Toxicodynamics,AD,10 E0.4,(2.5),AD,AF,=,ED,10H,ED,10A,实验动物与人之间差异,(,毒物动态学,),ED=Effective Dose(,有效作用剂量),31,Composite Uncertainty Factor,UF,C,=AK,AF,or AK,UF,x AD,AF,or AD,UF,x HK,AF,or HK,UF,x HD,AF,or HD,UF,UFc,:,综合不确定系数,NOAEL,LOAEL or,BMD,RfD or RfC,=,UF,C,32,33,Recent,Activities,最新版的国,际化学品安全司,(IPCS),化学物特异性调整系数,(CSAF),指导文件:,www.who.int/ipcs/methods/harmonization/areas/uncertainty/en/index.html,美国环境保护署,(US EPA),第一份基于化学物特异性调整系数,(CSAF),的化学物毒性评价,:,B,oron(,硼,)IRIS assessment,加拿大卫生部,(Health Canada),基于化学物特异性调整系数,(CSAF),的化学物毒性评价,:,TDIs,for ethylene glycol butyl ether(EGBE),Latest Development in,C,ancer Dose Response,A,ssessment,致癌物评价的最新进展,Cancer Slope Factor,(致癌反应斜率),Point of departure,36,Animal to human extrapolation is achieved by calculation of human equivalent oral dose.,EPA Cancer Guideline,“To derive a human equivalent oral dose from animal data,scale daily applied doses in proportion to body weight raised to the 0.75 power.”,致癌反应斜率,Dose,H,=,Dose,A,x(BW,A,/BW,H,),1/4,37,人群暴露剂量的推算,Oral dose in male rat chronic study=15 mg/kg-day,Male Fisher rat body weight=0.38 kg*,Human body weight=70 kg,Dose,H,=,Dose,A,x(BW,A,/BW,H,),1/4,=15 x(0.38/70),1/4,=4.1 mg/kg-day,*Note:animal default body weight can be found in,U.S.EPA 1988.Recommendations for and Documentation of Biological Values for Use in Risk Assessment.EPA/600/6-87/008,Central Compartment,(1),Peripheral Compartment,(2),k,12,k,21,k,e,摄入,药代动力学二室模型,排泄,Physiologically Based Pharmacokinetic Model(PBPK Model),生理药代动力学,Rapidly,perfused,tissues,Slowly,perfused,tissues,Blood,Fat,Lung,Liver,GI,Inhalation,Exhalation,Oral gavage/,Drinking water,Metabolism,IV,3,5,动物反应剂量,动物靶器官剂量,/,浓度,动物,PBPK Model,人群,PBPK Model,人群暴露剂量,用,生理药代动力学模型,(PBPK model),来,推算人群暴露剂量,Cancer Slope Factor,(致癌反应斜率),Point of departure,谢谢!,
展开阅读全文

开通  VIP、SVIP  下载更划算
下载10份以上建议开通 VIP 会员
下载20份以上建议开通SVIP会员


开通VIP      成为共赢上传

当前位置:首页 > 包罗万象 > 大杂烩

移动网页_全站_页脚广告1

关于我们      便捷服务       自信AI       AI导航        关注我们

©2010-2026 宁波自信网络信息技术有限公司  版权所有

客服电话:0574-28810668  投诉电话:18658249818

gongan.png浙公网安备33021202000488号   

icp.png浙ICP备2021020529号-1  |  浙B2-20240490  

关注我们 :微信公众号    抖音    微博    LOFTER 

客服